Connor, Clark & Lunn Investment Management (CC&L)
NVLN

Connor, Clark & Lunn Investment Management (CC&L)’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11,707
Closed -$108K – 974
2017
Q2 		$108K Sell
11,707
-45,622
-80% -$439K ﹤0.01% 783
2017
Q1 		$615K Sell
57,329
-111,906
-66% -$1.14M ﹤0.01% 589
2016
Q4 		$1.42M Buy
+169,235
New +$1.5M 0.01% 424

Other funds holding NVLN

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s NVLN Position: Q3 2017 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q3 2017, closing a stake of 11,707 shares — an estimated $108K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NVLN in Q4 2016 and held it in 3 quarters. The position peaked at $1.42M in Q4 2016. 72 funds tracked by Wall St. Rank hold NVLN as of Q3 2017.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q3 2017 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 11,707 Novelion Therapeutics Inc. Common Shares shares in Q3 2017, an estimated $108K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 3 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Novelion Therapeutics Inc. Common Shares position peaked at $1.42M in Q4 2016.
  • 72 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q3 2017.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2017, filed 14 Nov 2017.